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Correction of human phospholamban R14del
mutation associated with cardiomyopathy using
targeted nucleases and combination therapy
Ioannis Karakikes1,2,3,*, Francesca Stillitano1,*, Mathieu Nonnenmacher1,*, Christos Tzimas4, Despina Sanoudou5,
Vittavat Termglinchan2,3, Chi-Wing Kong6, Stephanie Rushing1, Jens Hansen7, Delaine Ceholski1,
Fotis Kolokathis8, Dimitrios Kremastinos8, Alexandros Katoulis8, Lihuan Ren6, Ninette Cohen9,
Johannes M.I.H. Gho10, Dimitrios Tsiapras11, Aryan Vink12, Joseph C. Wu2,3, Folkert W. Asselbergs10,13,14,
Ronald A. Li1,6, Jean-Sebastien Hulot1,15, Evangelia G. Kranias4,16 & Roger J. Hajjar1
A number of genetic mutations is associated with cardiomyopathies. A mutation in the coding
region of the phospholamban (PLN) gene (R14del) is identified in families with hereditary
heart failure. Heterozygous patients exhibit left ventricular dilation and ventricular arrhyth-
mias. Here we generate induced pluripotent stem cells (iPSCs) from a patient harbouring the
PLN R14del mutation and differentiate them into cardiomyocytes (iPSC-CMs). We find that
the PLN R14del mutation induces Ca2þ handling abnormalities, electrical instability, abnormal
cytoplasmic distribution of PLN protein and increases expression of molecular markers of
cardiac hypertrophy in iPSC-CMs. Gene correction using transcription activator-like effector
nucleases (TALENs) ameliorates the R14del-associated disease phenotypes in iPSC-CMs. In
addition, we show that knocking down the endogenous PLN and simultaneously expressing a
codon-optimized PLN gene reverses the disease phenotype in vitro. Our findings offer novel
strategies for targeting the pathogenic mutations associated with cardiomyopathies.
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D
ilated cardiomyopathy (DCM) is a leading cause of heart
failure characterized by biventricular dilatation and
progressive cardiac dysfunction and is often accompanied
by ventricular arrhythmias1. Recent studies have unravelled the
genetic basis of many forms of DCM, leading to the identification
of pathogenic DCM-causing mutations in a diverse set of
myocardial genes2, including phospholamban (also known as
PLN)3–6. PLN is a regulatory protein that controls Ca2þ cycling in
cardiomyocytes (CMs)7. PLN inhibits the cardiac isoform of the
sarcoplasmic reticulum (SR) Ca2þ ATPase (SERCA2a) in cardiac
myocytes thereby reducing influx of calcium into the SR. PLN is
phosphorylated at Ser16 by PKA or Thr17 by calcium/
calmodulin-dependent protein kinase II (CaMKII) or protein
kinase B (Akt). When phosphorylated at either or both of these
sites, the inhibition of SERCA2a is alleviated and calcium flux into
the SR increases. Several mutations in PLN have been identified in
patients and linked to hereditary DCM. The precise cardiac
pathology of the different PLN mutations varies but most patients
present with cardiac dilatation, hypertrophy, decreased ejection
fraction and ventricular arrhythmias. A deletion of amino acid
arginine 14 in the coding region of the PLN gene (R14del) was first
discovered in a large Greek family with hereditary DCM5 and
DCM patients heterozygous for the R14del mutation exhibit left
ventricular dilation, contractile dysfunction and episodic
ventricular arrhythmias, with overt heart failure by middle age
in some cases5,8,9. Although the molecular mechanism underlying
the pathogenesis of R14del-induced DCM remains unclear,
experimental evidence in a mouse model has suggested a link
between PLN R14del mutation and the impairment of cardiac
Ca2þ cycling, an effect that may be related to destabilization of
the pentameric structure of PLN and SERCA2a super inhibition5.
However, there was no effect on SERCA2a activity when the
R14del PLN was expressed in the PLN-null background mice10.
Interestingly, the R14 deletion of PLN has been associated with
both mild and severe forms of cardiomyopathy with variable
degrees of arrhythmias 5,8,11. More recently, a study found that
PLN R14del mutation carriers are at high risk for malignant
ventricular arrhythmias and end-stage heart failure, with left
ventricular ejection fractiono45% and sustained or nonsustained
ventricular tachycardia as independent risk factors12.
The ability to generate patient-specific human induced
pluripotent stem cells (iPSCs) offers new opportunities to study
the underlying mechanisms of DCM pathogenesis that can
eventually enable the development of personalized therapies.
Indeed, inherited cardiovascular diseases have been modelled in
iPSCs, including cardiac arrhythmia syndromes13–22,
arrhythmogenic right ventricular cardiomyopathy23, familial
hypertrophic cardiomyopathy24, Friedreich’s ataxia25 and
DCM26. The patient-specific iPSC-derived CMs recapitulate the
pathogenic disease phenotype and could provide opportunities
for novel insights into cardiac pathophysiology. The derived CMs
develop specific features such as abnormal contractile function,
dys-regulated calcium movements, altered electrical activities and
an increase in hypertrophic markers and can serve as a platform
to model the disease. When causative genetic mutations are
present, genome engineering using designer nucleases can be used
to correct the mutations. Three different types of molecular
scissors have been developed that can be designed to cut at
specific sites: (1) zinc finger nucleases, (2)transcription activator-
like effector nucleases (TALENs) and (3) clustered regularly inter-
spaced short palindromic repeats (CRISPR)27. Each of these
designer nucleases have unique features, and their capability to
target specific DNA sequences make them a very useful tool for
manipulating iPS cells.
In this study, we derived iPSC-CMs from a patient with
cardiomyopathy associated with a PLN R14del mutation to better
understand the link between mutant R14del and cardiac
pathophysiology. The patient-specific CMs displayed Ca2þ
handling abnormalities, electrical instability, abnormal cytoplas-
mic distribution of PLN protein and an increased expression of
molecular markers associated with cardiac hypertrophy. Using
TALEN-mediated gene editing, we corrected the PLNmutation in
iPSCs and the derived CMs display a normal phenotype.
Furthermore, the abnormal phenotype in iPSC-derived CMs
carrying the R14del mutation was reversed by a combinatorial
adeno-assisted vector (AAV)-mediated gene therapy approach to
knockdown the endogenous PLN while expressing a codon-
optimized human PLN.
Results
Derivation of iPSCs from a patient with PLN R14del mutation.
We obtained a skin biopsy from a female patient carrying a
heterozygous mutation in the PLN gene (c.40_42delAGA;
p.Arg14del) who belongs to a large family with a long clinical
history of hereditary DCM5 (VI 32 in Fig. 1 of ref. 5). The patient
presented with mild left ventricular systolic dysfunction,
ventricular chamber dilatation and frequent ventricular
arrhythmias. The typical sustained ventricular arrhythmias and
left ventricular dysfunction characteristic of these patients are
depicted in Fig. 1a and Supplementary Movie 1. Histopathological
examination of myocardial sections obtained from explanted
hearts of patients carrying the PLN-R14del mutation that derived
from a different founder showed an abnormal cytoplasmic
distribution and perinuclear accumulation of PLN (Fig. 1b),
suggesting that the R14del mutation is altering the intracellular
localization of the PLN. We generated three individual iPSC
clones (designated L1, L2 and L3) from patient-specific dermal
fibroblasts carrying the R14del mutation (hereafter referred to as
iPSC-R14del) using the synthetic modified messenger RNA
(mRNA) reprogramming system28 (Supplementary Fig. 1a). The
heterozygous mutation was verified by sequencing of the PLN
coding region in both the dermal fibroblasts and the fibroblast-
derived iPSC-R14del clones (Supplementary Fig. 1b). Multiple
assays were used to confirm the successful reprogramming of the
fibroblasts to iPSCs. Immunostaining analysis demonstrated that
the iPSC-R14del lines expressed the pluripotency markers
NANOG, OCT-3/4, SOX-2 and SSEA-4 (Fig.1c and Supplemen-
tary Fig. 1c). We also assessed pluripotency and tri-lineage
differentiation potential using real-time quantitative PCR assays.
We compared the gene expression profiles of the iPSC clones to a
reference set of embryonic stem cells (ESCs) and iPSC lines using
a bioinformatic scorecard approach29. The results showed that
the R14del-iPSC clones were transcriptional similar to the
reference set and differentiated into all three embryonic germ
layers in vitro (Supplementary Fig. 1d). Moreover, digital
karyotyping analysis showed that all the iPSC clones were
euploid and no chromosomal aberrations were observed
(Supplementary Fig. 1e).
Functional characteristics of iPS-CM with PLN R14del
mutation. We differentiated the iPSCs-R14del from the three
patient-specific clones (L1, L2 and L3) into CMs using a
directed differentiation method that yields a high percentage of
ventricular-like CMs30. After 15 days of differentiation, we
observed a widespread spontaneous beating activity of the iPSC-
R14del differentiation cultures (Supplementary Movie 2), which
is a characteristic of functional CMs (hereafter referred to as
R14del-CMs). Cultures of differentiated cells stained positive for
cardiac Troponin T, a marker of terminally differentiated CMs.
Also, we confirmed the expression of PLN in R14del-CMs
(Supplementary Fig. 2). As PLN plays a central role in
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modulating CM calcium (Ca2þ ) homeostasis by regulating the
activity of SERCA2a31, we next determined whether the R14del
mutation is affecting Ca2þ handling in iPSC-derived CMs. We
recorded the basal intracellular Ca2þ ([Ca2þ ]i) transients upon
electrical stimulation of R14del-CMs and WT-CMs loaded with
fura-2AM, a Ca2þ indicator. We observed a progressive
dysregulation of Ca2þ cycling in differentiated R14del-CMs,
which exhibited an arrhythmic Ca2þ cycling profile (Fig. 1d,e),
characterized by a higher spontaneous beating rate and frequent
episodes of irregular Ca2þ waves when compared with control
CMs (Fig.1f). Taken together, these data demonstrated
impairment in Ca2þ handling properties of iPSC-derived CMs
characterized by arrhythmias, suggesting a critical role of
abnormal Ca2þ handling in the pathogenesis of DCM induced
by the R14del mutation of PLN.
Genomic editing of iPSCs with PLN R14del mutation. Given
that epigenetic and transcriptional variation is common among
human pluripotent cell lines32, we sought to determine whether
the Ca2þ handling abnormalities observed in R14del-CM were
specifically induced by the R14del mutation. We developed a
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Figure 1 | Modelling of DCM using patient-specific iPSCs carrying a R14del mutation in PLN. (a) Twelve lead electrocardiogram from a patient showing
wide complex ventricular arrhythmias; (b) Representative immunohistochemistry images of PLN protein expression in explanted heart tissue from DCM
patients carrying the R14del mutation and patients diagnosed with ischaemic cardiomyopathy (ICM). Scale bar, 25mm; (c) Immunostaining for the
pluripotent markers OCT-3/4 and NANOG in R14del patient-specific iPSCs. Nucleus was counterstained with DAPI. Scale bar, 10mm; (d) Representative
Ca2þ transients of R14del-CMs during the course of differentiation; (e) Representative Ca2þ transients of control and R14del-CMs derived from three
independent iPSC clones at 36 days post differentiation, s¼ seconds. (f) Quantification of percentages of control and R14del-CMs exhibiting irregular
Ca2þ transients at day 36 of differentiation. The beating rate was measured as number of events (peaks) per time (sec) during a stimulation of 0.5Hz.
Irregular Ca2þ transients were determined by quantifying the percentage of beating areas exhibiting irregular Ca2þ transient. The number of irregular
peaks were counted during each recording for 1min at 0.5Hz. Values represent mean±s.d. (n¼ 13 of R14del-CMs derived from two independent iPSC
clones L2 and L3). *Po0.05 (unpaired student’s t-test).
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TALEN vector pair33 designed to introduce a double-strand break
adjacent to the R14del mutation of the PLN and validated its
efficiency by the surveyor assay34 (Supplementary Fig. 3). Patient-
derived iPSCs were co-transfected with a PLN-specific TALEN
pair together with the gene correction matrix (Fig. 2a). We
obtained two isogenic iPSC clones, designated L2GC1 and
L2GC2, which differ only in the R14del mutation with the
parent clone L2. The corrected clones were expanded and the
correction of the R14del mutation was confirmed by Sanger
sequencing (Fig. 2b and Supplementary Fig. 4). Similarly to the
parental line, the TALEN-edited isogenic iPSCs clones were
characterized and confirmed to be pluripotent and karyotypically
normal (Supplementary Fig. 5). We differentiated the corrected
clones into CMs, and determined that the targeted gene
correction did not alter the gene expression level of PLN and
appropriate expression of the ‘TALEN-corrected’ allele was
confirmed in the isogenic CMs of both clones by
pyrosequencing (Fig. 2c). In addition, we performed whole-
exome sequencing and bioinformatics analyses to assess off-target
mutagenesis. Consistent with recent reports35–37, exome
sequencing of the parental and TALEN-corrected iPSCs showed
that off-target mutations attributable to the TALENs were very
rare (Supplementary Table 1). Next we sought to determine
whether the genetic correction of the R14del mutation resulted in
functional phenotypic correction. We observed that TALEN-
corrected CMs displayed a normal Ca2þ cycling phenotype
(Fig. 3a–c), and a significantly lower resting diastolic Ca2þ levels
compared to CMs derived from the the parent line
(Supplementary Fig. 6). Previously, it was shown that Ca2þ -
induced Ca2þ release machinery is functional in iPSC-derived
CMs38. Indeed, caffeine application elicited an instantaneous and
rapid release of Ca2þ from the intracellular stores of CMs,
resulting in high amplitude Ca2þ transients (Fig. 3d). Consistent
with the hyperdynamic basal function of the R14del PLN10, the
caffeine-induced Ca2þ amplitude was significantly higher in the
R14del-CMs when compared with the TALEN-corrected CMs
(Fig. 3e). Also, single-cell electrophysiological analysis demon-
strated that R14del-CMs showed faster depolarization rate and
significantly more depolarized maximum diastolic potential than
the TALEN-corrected CMs (Fig. 4a,b and Table 1). In addition,
the corrected CMs showed a regression of the hypertrophic
phenotype, as evidenced by the reduced expression of the
hypertrophic markers ANF, BNP and an increased MYH6/
MYH7 ratio (Fig. 4c). Interestingly, we observed that the
subcellular distribution of the PLN protein in R14del-CMs was
predominantly polarized at one side of the cytoplasm (Fig. 5),
recapitulating the phenotype observed in the cardiac tissue
sections of the R14del patients. In contrast, the corrected CMs
displayed a homogeneous reticular distribution of PLN (Fig. 5).
Taken together, these data strongly suggest that targeted gene
correction of R14del PLN mutation is sufficient to fully restore a
normal cardiac phenotype ex vivo.
Correction of PLN R14del mutation by gene transfer in
iPS-CMs. To achieve PLN correction by a combinatorial gene
therapy approach, we engineered an AAV type 6 monocistronic
vector allowing the knockdown of endogenous PLN by an intronic
artificial microRNA (miR-PLN), together with overexpression of a
microRNA (miRNA)-resistant, codon-optimized PLN (Fig. 6a).
Self-complementary genomes were packaged into AAV6 capsids,
which allow a high transduction efficiency of cardiac cells39. These
vectors were used to infect R14del-CMs and allowed very high
expression of wt PLN, together with B50% knockdown of
endogenous PLN transcripts (Fig. 6b and Supplementary Fig. 7).
Importantly, miR-mediated PLN knockdown was highly specific
with no off-target effects, as assessed by RNA sequencing and
bioinformatics analyses (Supplementary Fig. 8). Interestingly,
AAV6-mediated overexpression of PLN induced a down-
regulation of endogenous PLN transcripts, suggestive of a
negative feedback mechanism since the steady-state level of PLN
in CMs is tightly regulated40 (Fig. 6b). To determine whether
AAV6 vectors could rescue the Ca2þ abnormalities associated
with the R14del mutation, we recorded the basal [Ca2þ ]i
transients in R14del-CMs. Seven days post AAV6 infection, we
observed that AAV6-mediated PLN overexpression reduced the
frequency of arrythmogenic episodes when compared with
non-infected cells (Fig. 6c). The expression of the cardiac
hypertrophy markers, ANF and BNP, was significantly increased
following infection by control AAV6 particles, suggesting a
general effect of AAV vectors on CM stress and homeostasis.
However, infection by AAV6 encoding PLN resulted in a
significant decrease of ANF expression down to a level
comparable to that of normal iPSC-CMs (Fig. 6d). By contrast,
BNP expression was not reduced down to the level observed in
WT-CMs. Viral-mediated PLN expression also increased the
MYH6/MYH7 ratio of R14del-CM to a level exceeding that of
normal CMs (Fig. 6e). Neither marker was significantly altered by
the presence of PLN miRNA versus control miRNA, suggesting
that overexpression of wild-type PLN alone is sufficient to
improve CM functions without the suppression of mutant PLN.
These findings suggest that AAV6-mediated overexpression of
wild-type PLN was able to rescue the impaired calcium handling
characteristics in R14del-CMs in vitro.
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Discussion
In this study, we demonstrate that CMs differentiated from
mutant iPSCs, derived from a patient harbouring a deleterious
R14del mutation in the PLN gene, display disease-specific
irregular Ca2þ handling and abnormal cytoplasmic distribution
of PLN protein. This irregularity in calcium cycling correlates
well with the fatal arrhythmias observed in R14del patients. In
addition, we observed an increase in the markers of cardiac
hypertrophy and an abnormal cytoplasmic PLN protein distribu-
tion in CMs. Importantly, the abnormal PLN distribution was
also observed in the myocardium of R14del patients. Using either
a TALEN-mediated gene correction or a combinatorial gene
therapy approach, we rescued the disease phenotype in vitro.
Genome engineering has been used to introduce disease genes
in iPSCs to recapitulate disease phenotypes. In a recent study, the
ion channel genes KCNQ1 and KCNH2 with dominant negative
mutations causing Long QT syndrome (LQTS) type-1 and -2,
respectively, were introduced into both ESCs and iPSCs using
zinc finger nucleases41. The investigators then derived CMs,
which displayed characteristics of LQTS phenotype including
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Figure 3 | Gene correction ameliorates Ca2þ abnormalities. (a) Representative Ca2þ transients of cardiomyocytes derived from WT-, L2- and isogenic
TALEN-corrected (L2GC1 and L2GC2) clones at 36 days post differentiation. (b) Beating frequency. (c) Quantification of percentages of isogenic CMs
exhibiting irregular Ca2þ transients at day 36 of differentiation. The beating rate was measured as number of events (peaks) per time (sec) during a
stimulation of 0.5Hz. Irregular Ca2þ transients were determined by quantifying the percentage of beating areas exhibiting irregular Ca2þ transient. The
number of irregular peaks were determined during each recording for 1min at 0.5Hz. Mean±s.d. (n¼ 13 recordings of L2-CMs; n¼ 16 recordings of L2GC1;
n¼40 recordings of L2GC1); *Po0.05 (ANOVA, Tukey’s Multiple Comparison Test). (d) Representative caffeine-induced Ca2þ transients in single cells;
(e) Amplitude analysis of caffeine-induced Ca2þ transients in single cardiomyocytes. A caffeine puff (10mmol l 1) was applied and caffeine-induced
amplitude was assessed. Values represent mean±s.e.m. (n¼ 15 L2-CM and n¼4 L2GC2-CM). *Po0.05 (unpaired student’s t-test).
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prolongation of the action potential duration, recapitulating the
key pathophysiological features of LQTS types 1 and 2. In another
study, Wang et al.42 modelled Barth syndrome, a mitochondrial
cardiomyopathy disorder caused by mutation of the gene
encoding Tafazzin (TAZ), with iPSCs obtained from patients
affected by the disease or by Cas9-mediated genome editing to
mutate TAZ in a control human line. Gene replacement and gene
editing demonstrated that CMs exhibited metabolic, structural
and functional abnormalities associated with TAZ mutations.
In vivo correction has also been performed in murine models.
In a recent study by Jiang et al.43 the expression of a hypertrophic
cardiomyopathy (HCM) causing mutation (Myh6 R403Q) was
decreased in mice using RNA interference (RNAi). AAV-
mediated Myh6-R403Q knockdown resulted in a reversal of
myocardial fibrosis for B6 months43. In a separate study,
Mearini et al.44 targeted a frame shift mutations in myosin-
binding protein C3 (Mybpc3), encoding cardiac MyBP-C
(cMyBP-C) associated with HCM. Administration of AAV9-
Mybpc3 in 1-day-old transgenic mice prevented the development
of cardiac hypertrophy and dysfunction for a period of 34
weeks44. In our study, we used a combinatorial gene therapy
approach with knockdown of the endogenous mutant gene along
with re-expression of the normal PLN gene. This gene therapy
approach based on AAV9 delivery could be tested in vivo in an
appropriate murine model of DCM carrying the R14del mutation.
Our findings may pave the way for the development of novel
therapies of pathogenic mutations associated with inherited
cardiomyopathies.
Methods
iPSC reprogramming. Dermal fibroblasts were obtained from a skin biopsy
of a 42-year old volunteer following informed consent (Onassis Cardiac Surgery
Center, Athens, Greece). Integration-free iPSC clones were generated from the
patient’s dermal fibroblasts carrying the R14del mutation using the synthetic
modified mRNA reprogramming system28. Briefly, a reprogramming cocktail
of five human mRNA reprogramming factors encoding OCT-3/4, SOX-2,
c-MYC, KLF-4 and LIN-28 was used according to the manufacturer’s protocol
(Stemgent). Each mRNA factor was added at a concentration of 100 ng ml 1,
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Figure 4 | Gene correction improves elephysiological and hypertrophic phenotypes. (a) Representative action potentia (AP) waveforms of
spontaneously beating cardiomyocytes. The AP properties of single cells were analysed using the patch-clamp method; (b) Analysis of maximum diastolic
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normalized to GAPDH housekeeping gene and presented as MYH6/MYH7 ratio. Values represent mean±s.e.m. (n¼6 per group). *Po0.05
(unpaired student’s t-test). NS, not significant.
Table 1 | Action potential parameters in mutated (L2) and
isogenic (L2-GC2) CMs.
Parameters L2-CM
n¼ 14
L2-GC2-CM
n¼ 22
Frequency (Hz) 0.66±0.07 0.55±0.05
APA (mV) 59.30±3.70 58.20±2.20
Upstroke velocity (mVms 1) 3.56±0.54 1.97±0.24*
Decay velocity (mVms 1) 0.33±0.04 0.29±0.04
APD90 (ms) 543±74 710±69
MDP (mV) 49.3±1.50  57.70±2.40#
APA, action potential amplitude; APD90, AP duration measured at 90% repolarization; CM,
cardiomyocyte; MDP, maximum diastolic potential; iPSC, induced pluripotent stem cells; TALEN,
transcription activator-like effector nucleases.
Data are represented as mean±s.e.m. Two-tailed Student’s t-test was used to test the mean
between groups, *Po0.05, #Po0.01.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7955
6 NATURE COMMUNICATIONS | 6:6955 | DOI: 10.1038/ncomms7955 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
resulting in an mRNA reprogramming cocktail with a stoichiometric ratio of
3:1:1:1:1 (for OCT-3/4, SOX-2, c-MYC, KLF-4 and LIN-28, respectively). The
mRNA cocktail was delivered to the dermal fibroblasts cells daily using RNAiMAX
Transfection Reagent (Invitrogen) diluted in Opti-MEM Medium (Invitrogen).
Transfections were repeated at 24-h intervals for 15 days. Cell colonies were
manually picked after B21 days and were propagated under feeder-independent
conditions as described45. Briefly, iPSC lines were maintained in the mTeSR1
(Stem Cell Technologies) media on tissue culture plates coated with hESC-qualified
Matrigel (BD Biosciences) in 5% CO2/5% O2/90% N2 environment at 37 C.
Differentiation of iPSC into CMs. The iPSC cells were differentiated into CMs
using a direct differentiation method46. Cardiomyocyte differentiation was initiated
in suspension cultures on ultra-low attachment dishes (Corning) in mTESR1
medium supplemented with BMP4 (10 ngml 1) and Blebbistatin (5 mM) for 24 h.
The medium was then replaced with the basal differentiation medium (StemPro34,
50mgml 1 ascorbic acid, 2mM GlutaMAX-I) supplemented with BMP4
(10 ngml 1) and Activin-A (25 ngml 1) for 48 h (days 1–3) and then switched to
basal differentiation medium for another 36 h (days 3–4.5). Finally, the cells were
differentiated in basal differentiation medium supplemented with IWR-1 (2.5 mM)
for 96 h (day 4.5–8.5). The differentiated CMs were maintained in basal
differentiation media for up to 4 weeks. All cytokines were purchased from R&D
systems. The small molecules were purchased from Sigma. All differentiation
cultures were maintained in 5% CO2/air environment.
Calcium transient analysis. At 30-days post differentiation, iPSC-derived CMs
were dissociated, plated on matrigel-coated coverslips and cultured in basal
medium for 72–96 h. The CMs were loaded with a fluorescent Ca2þ sensitive dye,
Fura-2, and the ratios of fluorescence intensities (excited at 340 and 380 nm) were
recorded using the Ionoptix system (Ionoptix). The electrically induced Ca2þ
transients ([Ca2þ ]i) were triggered by pulses generated from a field stimulator
(20ms duration, 0.5Hz). The Ca2þ traces were analysed using IonWizard software
to calculate the irregularity of the timing (Beating rate), the percentage of irregular
beating areas and the number of irregular waveforms.
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Figure 6 | AAV-mediated gene therapy. (a) Map of AAV vectors. The asterisk denotes the ITR mutation necessary for self-complementary genome
packaging; (b) Transduction of iPS-CMs by self-complementary AAV vectors pseudotyped in AAV6 capsids. CMs derived from R14del-iPSC cells were
infected at an MOI of 4 104 viral genomes per cell on day 28 post differentiation. Transduction efficiency was measured 7 days post infection by green
fluorescent protein fluorescence (left; scale bar,100mm) or qRT–PCR with primers specific for the endogenous and viral PLN (PLNwt and PLNcm,
respectively). Values are normalized to uninfected R14del-CMs; (c) Representative traces of intracellular Ca2þ transient waves of electrically stimulated
(0.5Hz) R14del-CMs performed 7 days post infection with the indicated AAV6 constructs; (d) Expression of cardiac hypertrophy markers ANF and BNP
measured by qRT–PCR and normalized to GAPDH expression. Values are expressed as relative expression to WT-CMs; (e) Gene expression analysis of the
myosin heavy chain isoforms ratio, MYH6/MYH7, measured by qRT–PCR. Values are normalized to WT-CMs. (b,d,e) Values represent the meanþ s.d.
(n¼ 3). *Po0.05, **Po0.01, ***Po0.001, NS¼ P40.05 (unpaired student’s t-test). NS, not significant.
WT-CMs L2-CMs L2GC2-CMs
DNA/cTNT/PLN DNA/cTNT/PLNDNA/cTNT/PLN
Figure 5 | PLN protein distribution in cardiomyocytes. Representative immunofluorescence images showing the intracellular protein distribution of
phospholamban (PLN) and cardiac troponin T (cTNT) in WT-, L2- and L2GC2-CMs. Nuclei were counterstained with DAPI. Scale bar, 25mm.
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TALEN construction. TALEN genomic binding sites were designed using the
TALEN Hit software (Cellectis Bioresearch). The TALEN genomic binding sites
were 17 bp in length and the target sequence between the two binding sites was
17 bp in length (TALEN left: 30-TTTATCAATTTCTGTCT-50 ; TALEN right: 30-
TGATACAGATCAGCAAG-50) separated by a 15 bp spacer. The homologous
recombination (HR) matrix design, which spanned (nucleotides) nts 10,183 to
11,282 of the PLN gene, incorporated two silent mutations within each TALEN
binding site, to prevent matrix DNA cleavage. The HR matrix was synthesized by
Genescript and a PGK-Puromycin-2A-EGFP-SV40polyA selection cassette flanked
by loxP sites was inserted in a unique BglII restriction site downstream of the PLN
stop codon.
Surveyor assay. The efficiency and specificity of the TALEN-induced modifica-
tion of the PLN locus was validated by the SURVEYOR assay (Transgenomic)
according the manufacturer’s protocol. Briefly, TALENs were transfected into
HEK-293T cells and 72 h later genomic DNA was extracted. The PLN locus was
amplified by PCR (forward primer: 50-GAGAGAGAGAGAGGGAGAGAGAC-30
and reverse primer: 50-GAAGTGAACTTGTTGGCAGTGCAG-30) and the PCR
amplification products were re-annealed, digested by the Surveyor nuclease and
subjected to agarose gel electrophoresis to confirm TALEN-induced mutations.
Isolation of targeted clonal cell populations. iPS-R14del cells were co-trans-
fected with TALENs and HR matrix by electroporation47. On the day of the
electroporation, semi-confluent cell cultures were dissociated into single cells with
0.025% trypsin for 5min at 37 C and 107 cells were electroporated with a mix of
50mg of the TALEN pair (25 mg of each plasmid) and 15 mg of the HR matrix in a
0.4 cm cuvette using the parameters 250V and 500mF. Following electroporation,
the cells were re-plated at a low density and allowed to grow for about 5 days.
Transfected clones were selected by puromycin (0.5 mgml 1) for a period of 7
days. Puromycin-resistant colonies were picked up and transferred in duplicate
into a matrigel-coated 48-well plate. Cells from one 48-well plate were used for
DNA preparation B1 week later. Bona fide junctions between chromosome 6 and
PLN matrix were screened by PCR using the forward primer 50-
GACCAGAAATATGCTATAGGAACTTAAC-30 located on chromosome 6
upstream of the PLN matrix (PLN genomic positions 10,084–10,111) and the
reverse primer 50-CAGGGCTGCCTTGGAAA-30 located in the PGK promoter of
the selection cassette. To genotype the PLN allele present on the intact
chromosome, a 746-nt fragment extending from PLN genomic positions 10,398 to
11,143 was amplified and digested with SapI endonuclease, which cuts only wild-
type PLN, yielding two fragments of 464 and 279 nts (Supplementary Fig. 4).
AAV vectors. Following selection of the best miRNA candidates, a SnaBI-NotI
fragment containing most of the CMV promoter, the intronic miRNA and the
EGFP sequence was excised from pSM155 vectors and inserted into the corre-
sponding sites of self-complementary scAAV-EGFP48 to obtain scAAV-miRNA-
EGFP vectors. To achieve simultaneous wild-type PLN overexpression, a codon-
optimized miRNA-resistant version of PLN (PLNco) was synthesized and inserted
between AgeI and NotI sites, in lieu of the EGFP, yielding scAAV-miR-PLNco
vectors. scAAV vectors were pseudotyped into AAV6 capsids using the pDP-6
vector49 and purified by iodixanol gradient and dialysis. Viral titres were measured
by real-time PCR using primers specific for the SV40 polyadenylation signal.
IPS-CMs were infected at day 25 after the onset of differentiation using an
multiplicity of infection (MOI) of 4 104 viral genomes per cell.
Artificial microRNA screening. Intronic artificial miRNAs directed against PLN
were cloned into the pSM155 vector50, kindly provided my Michael A. Frohman
(Stony Brook University, NY), using asymmetric BsmBI restriction sites
(Supplementary Fig. 7). For amiRNA candidates screening, a reporter construct
was obtained by inserting the full-length human PLN complementary DNA
(cDNA; amplified by PCR from human heart cDNA) downstream of the luciferase
coding sequence of the pGL3-control plasmid (Promega). For the PLN-R14del
reporter vector, a pair of complementary primers encoding mutant PLN was
annealed and inserted in the same position of pGL3-control vector. HEK-293T
cells were co-transfected with both pSM155-amiRNA and reporter vectors in a 5:1
ratio using calcium phosphate transfection, and luciferase activity from cell lysates
was measured 24 h post transfection using Luciferase assay reagent (Promega).
Transfection efficiency was normalized by measuring the green fluorescent protein
fluorescence from pSM155 vectors. PSM155 vectors containing a scrambled
miRNA or a luciferase-directed miRNA were used as negative and positive
controls, respectively.
Immunocytochemistry. iPSC were cultured on matrigel-coated coverslips, fixed in
paraformaldehyde and permeabilized in blocking/permeabilization buffer (2%
BSA/2% FBS/0.05% NP40 in PBS) for 45min and incubated with primary anti-
bodies overnight at 4 C. Then the cells were washed in PBS and incubated with
Alexa-conjugated secondary antibodies (Invitrogen) diluted in blocking/permea-
bilization buffer (1:750). Finally, after washing in PBS the cells were counterstained
with 4,6-diamidino-2-phenylindole (DAPI). Immunofluorescence images were
acquired using an Olympus X41 microscope. The following antibodies were used:
mouse monoclonal anti-OCT4 (1:100, Santa Cruz), goat polyclonal anti-NANOG
(1:100, R&D systems), mouse monoclonal anti-SOX2 (1:100, R&D systems) and
mouse monoclonal anti-SSEA-4 (1:100, R&D systems). Similarly, iPSC-derived
CMs were dissociated and cultured on matrigel-coated coverslips for 4–5 days,
fixed in paraformaldehyde and permeabilized in blocking/permeabilization buffer
for 45min. The cells were incubated with Alexa-conjugated primary antibodies
overnight at 4 C, washed in PBS and counterstained with DAPI. Confocal imaging
was performed using a Leica SP5 confocal system. The following antibodies were
used: mouse monoclonal anti-cardiac troponin T (1:200, Thermo Fisher Scientific)
and mouse monoclonal anti-PLN (1:200, Bradilla).
Immunohistochemistry. Myocardial tissues were obtained from the explanted
hearts of patients carrying the PLN-R14del mutation (n¼ 2) and patients with
ischaemic cardiomyopathy (n¼ 2) at the time of cardiac transplantation at the
University Medical Center Utrecht (Department of Cardiology, Division Heart and
Lungs, Utrecht, The Netherlands) with patients’ consent and an approved protocol
by the center’s Institutional Review Board. Myocardial samples were derived from
the left ventricular septum and posterolateral walls of PLN-R14del patients, and
remote (non-infarcted) areas of ischemic cardiomyopathy patients. The explanted
heart tissues were fixed in 10% neutral-buffered formalin processed by standard
protocol and embedded in paraffin. Four-micron-thick tissue sections were
deparaffinized in xylene and rehydrated in graded alcohols. Antigen retrieval was
performed in a sodium citrate buffer (pH 6.0) in a pressure cooker. Myocardial
sections were washed in PBS, incubated in blocking buffer (5% normal donkey
serum in PBS) for 30min at room temperature, followed by primary antibodies,
rabbit polyclonal anti-Serca2a (1:100) and mouse monoclonal anti-PLN (1:100) at
4 C overnight. After three washes in PBS, sections were incubated for 60min with
1:750 secondary antibodies (anti-rabbit Alexa-555 and anti-mouse Alexa-488).
Confocal imaging was performed using a Leica SP5 confocal system.
Quantitative RT–PCR. Relative gene expression was determined using a two-step
quantitative real-time PCR method. Total RNA was isolated with the RNeasy
Isolation kit with on-column DNase I treatment (Qiagen) and reverse-transcribed
using the cDNA Synthesis Kit (Quanta biosciences). Quantitative reverse tran-
scription PCR (RT–PCR) was performed with the Quanta SYBR Green Supermix
(Quanta biosciences) on the ABI Prism 7500 Real-Time PCR System (Applied
Biosystems). Fold changes in gene expression were determined using the com-
parative CT method (DDCt) with normalization to the housekeeping genes GAPDH
or B2M. The primer sequences used in the study are shown in Supplementary
Table 2. The TaqMan hPSC Scorecard panel was used to assess pluripotency and
trilineage differentiation potential according to manufacturer’s instructions (Life
Technologies). Data analysis was performed using the hPSC Scorecard software
(Life Technologies).
Pyrosequencing analysis. PCR templates for pyrosequencing were amplified
from cDNA using PrimeSTAR GXL DNA Polymerase (Clontech) following the
manufacturer’s instructions. The pyrosequencing was performed using the Pyro-
Mark Q24 (Qiagen) and pyrograms were analysed using the PyroMark Q24
Software 2.0.
SNP karyotyping. Single nucleotide polymorphism (SNP) karyotype analysis was
performed on the Illumina’s CytoSNP-850K genotyping microarrays, which
measure B850,000 SNPs across the genome. All genomic DNA was isolated from
iPSC clones according to the manufacturer’s protocol (QIAGEN). Input genomic
DNA (500 ng) was processed, hybridized to the array and scanned on an Illumina
HiScan according to the manufacturer’s instructions. Copy number variations
(CNVs) were identified using the cnvPartition Pluginv.3.2.0 in GenomeStudio
(Illumina) by assessing both the B-allele frequency and Log R ratios.
Single-cell electrophysiology and Ca2þ imaging. The patch-clamp and Ca2þ
imaging assays were performed on single CMs isolated from the differentiated
cardiospheres and seeded on matrigel-coated glass coverslips or glass bottom dish.
Assays were performed 5–7 days post seeding (30–50 days post differentiation).
Patch-clamp studies. The action potentials were recorded by whole-cell patch-
clamp technique using the EPC10 amplifier and Pulse/PulseFit software (HEKA,
Germany) at 37 C. The patch pipettes were prepared to have a typical resistance of
3–6MO. The internal pipette solution contained 110mM potassium aspartate,
20mM KCl, 10mM HEPES, 1mM MgCl2, 0.1mM ATP (disodium salt), 5mM
ATP (magnesium salt), 5mM phosphocreatine (disodium salt) and 1mM EGTA
(pH 7.2). The external bath solution contained 140mM NaCl, 5mM KCl, 1mM
MgCl2, 10mM D-glucose, 1mM CaCl2 and 10mM HEPES (pH 7.4).
Ca2þ imaging. Ca2þ imaging was carried out with a spinning disk confocal
microscope (PerkinElmer, USA) at 37 C. Ca2þ -sensitive dye, X-Rhod 1 (Invi-
trogen, 1.5 mM, 15min at 37 C), was loaded into the isolated CMs, followed by
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washing and subsequent 5min incubation in the same HEPES buffered external
solution as used in the patch-clamp experiment. Diastolic Ca2þ level were esti-
mated as the background-corrected fluorescence intensity of X-Rhod 1 without any
stimulation. Ca2þ transient recordings were sampled at 33Hz. Electrically induced
Ca2þ transients were triggered by an isolated field stimulator (40V cm 1, 20-ms
pulse at 0.5Hz); caffeine-induced Ca2þ transients were triggered with a puff of
caffeine (10 mM). Fluorescence intensity of CMs in sequences of time-lapse images
recorded was converted to numerical data with Image J (NIH, US), followed by
mathematical treatment with Origin (OriginLab, Northampton, MA) to obtain the
Ca2þ transient parameters including the transient amplitude, resting Ca2þ ,
maximum upstroke and decay velocity and decay constant.
RNA-seq analysis. Cardiomyocytes derived from PLN-R41del iPSC cells were
infected with AAV6-EGFP-miR-PLN or AAV6-EGFP-miR-luc as a negative con-
trol at an MOI of 104. One week after infection, total RNA was extracted using
Zymo columns and 2 mg were used to generate a RNA-seq sequencing library. Poly-
A selection and mRNA-SEQ library preparation were performed at the Mount
Sinai Genomics Core Facility. Sequencing (50 bases, paired ends) was performed
using a Illumina HiSeq2500. Annotated reads were obtained using STAR and
HTSeq and normalized to full library size. Scatter plots of read counts were realized
using Graphpad PRISM. For the Venn diagram analysis, 41 human transcripts
showing significant homology to the PLN miRNA target sequence (30-GCTA-
TAAGAGCCTCAACCATT-50) were identified using BLASTn, and compared with
the 381 transcripts significantly downregulated in cells expressing miR-PLN versus
control cells expressing miR-Luc. A surface-proportional Venn diagram was
obtained using the BioVenn application (http://www.cmbi.ru.nl/cdd/biovenn/
index.php). RNA-seq data have been deposited in GEO (Gene Expression Omni-
bus) under accession code GSE65763.
Exome sequencing. Genomic DNA samples were assessed for quantity by Qubit
fluorometry (Life Technologies, Grand Island, NY) and for quality by the 2100
Bioanalyzer system (Agilent). Initial shearing of 0.5–1 mg genomic DNA to an
average of 200–300 bp fragments was performed using the Covaris E210 focused
acoustic energy system (Covaris). Whole genome libraries were prepared using the
NEBNext DNA Library Prep kit according to the standard manufacturer’s protocol
(New England Biolabs). Illumina compatible paired-end adapters were used and
the adapter-ligated DNA fragments was amplified by ligation-mediated PCR
(KAPA Biosystems) using a reverse PCR primer containing a 6 nt barcode that
allowed for multiple samples to be pooled and sequenced in the same run. The
library was enriched for human exomic sequences using the SeqCap EZ Human
Exome Library v3.0 capture system (Roche NimbleGen). The libraries were then
sequenced with a 100 bp paired-end protocol on the Illumina HiSeq2500 according
to the manufacturer’s protocol (Illumina). Exome sequencing data have been
deposited in GEO under accession code GSE65763.
Identification of novel indels. Off-target indels were identified by computational
approach35. Paired-end reads were aligned to the human reference genome hg19
using Bowtie-2.1.0, followed by manipulation using PicardTools-1.110 (sorting,
duplicate marking, readGroup addition and indexing). The Genome Analysis
ToolKit (GATK), version 3.1.1, was used for indel identification. Sample processing
included local realignment via ‘RealignmentTargetCreator’ and ‘IndelRealigner’,
base score recalibration via ‘BaseRecalibrator’, variant calling across the three
samples via ‘HaplotypeCaller’ and variant score recalibration via
‘VariantRecalibrator’ and ‘ApplyRecalibration’.
The set of identified indels was filtered in several steps. To remove indels near
low-complexity regions the hg19 RepeatMasker database was downloaded from
UCSC Genome Browser website. Every indel that contained a masked base pair
within a distance of 10 bp or433 masked basepairs within a distance of 50 bp was
removed. None of the identified indels caused expansions or compression of long
(46 bp) homopolymer, so no indels were removed at this step. To generate a list of
sample specific indels only indels with differing alternative alleles in both clones
(L2GC1 and L2GC2) were kept. In addition, we removed all those indels in which
the alternate allele was not covered by at least three reads. To identify indels that lie
close to possible off-target TALEN binding sites, we generated a list of sequences by
substituting r5 bp of each monomer’s on-target binding site and aligned them to
the reference genome hg19 using bowtie. Indels that are located within 100 bp of
genomic binding positions were considered to lie next to an off-target binding site.
About 16,500 TALEN off-target binding sites were located on opposite strands and
separated by 10–22 bp and were considered as paired.
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